Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birtamimab in Mayo Stage IV AL Amyloidosis
NCT04973137Phase 3Terminated
- Sponsor
- Prothena Corporation
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of birtamimab in light-chain amyloidosis, sponsored by Prothena Corporation. Started Aug 2021; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT04973137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973137.